Elite in Hemolytic-Uremic Syndrome

Eric Rondeau

Paris, FR 
Elite in Hemolytic-Uremic Syndrome
Paris, FR 
OverviewLocationsClinical Research

Overview

Eric Rondeau practices in Paris, France. Mr. Rondeau is rated as an Elite expert by MediFind in the treatment of Hemolytic-Uremic Syndrome. His top areas of expertise are D-Plus Hemolytic Uremic Syndrome, D-Minus Hemolytic Uremic Syndrome, Hemolytic-Uremic Syndrome, Atypical Hemolytic Uremic Syndrome (aHUS), and Kidney Transplant.

His clinical research consists of co-authoring 179 peer reviewed articles and participating in 1 clinical trial. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 32 articles and participated in 1 clinical trial in the study of Hemolytic-Uremic Syndrome.

Gender
Male

Locations

Paris, France
Other Locations
75020, France
Nancy, 54000, France
Strasbourg, France
CHU de Tours
Tours, France

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

1 Clinical Trials

Multicentric, Prospective Open-label Study Assessing an Algorithm-based Strategy of Eculizumab Discontinuation in Children and Adults With Atypical Hemolytic Uremic Syndrome (aHUS)
Multicentric, Prospective Open-label Study Assessing an Algorithm-based Strategy of Eculizumab Discontinuation in Children and Adults With Atypical Hemolytic Uremic Syndrome (aHUS)
Enrollment Status: Completed
Publish Date: December 06, 2019
Intervention Type: Drug
Study Phase: Phase 4

179 Total Publications

Partial endothelial-to-mesenchymal transition associates with endothelial HLA II expression and precedes the development of de novo donor specific anti-HLA antibodies in kidney recipients experiencing a delayed graft function.
Partial endothelial-to-mesenchymal transition associates with endothelial HLA II expression and precedes the development of de novo donor specific anti-HLA antibodies in kidney recipients experiencing a delayed graft function.
Journal: American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons
Published: January 20, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Rondeau's expertise for a condition
ConditionClose
View All 30 Experienced Conditions
Want to save this expert for later?
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile